Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase RegistryAnnamaria Brioli, Michael Lauseker, Ulla Olsson‐Strömberg et al.|Leukemia|2024Cited by 25
The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation ProgramTomasz Sacha, Olga Grzybowska‐Izydorczyk, Elżbieta Szczepanek et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 7
Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis RegistryAnnamaria Brioli, Michael Lauseker, Elza Lomaia et al.|Blood|2022Cited by 3
A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year ReportTomasz Sacha, Olga Grzybowska‐Izydorczyk, Elżbieta Szczepanek et al.|Blood|2020Cited by 1